Authors
Bruno Meduri, Antonella Baldissera, Cinzia Iotti, Luc J E E Scheijmans, Marcel R Stam, Salvatore Parisi, Liesbeth J Boersma, Ilario Ammendolia, Eveline Koiter, Paola Canino, Dianne M Busz, Marika Stenfert Kroese, Patrizia Giacobazzi, Maria P Ruggieri, Antoine Engelen, Tindara Munafò, Karolien Verhoeven, Mariacarla Valli, Roberto Vicini, Riccardo Cuoghi Costantini, Elisa D'Angelo, Frank Lohr, Roberto D'Amico, Giovanni Frezza, Philip Poortmans, for the IRMA Trialists, IRMA Trialists
Published in
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Pages JCO2600969. Nov 17, 2026. Epub Nov 17, 2026.
Abstract
The aim of this study was to investigate whether external-beam accelerated partial-breast irradiation (APBI) provides noninferior local control compared with whole-breast irradiation (WBI).
We conducted this randomized phase III trial (ClinicalTrials.gov identifier: NCT01803958) in 35 centers. Patients age ≥49 years with invasive breast cancer, resection margins ≥2 mm, tumor diameter ≤3 cm, and pN0-1 were randomly assigned 1:1 to WBI or APBI (38.5 Gy in 10 fractions twice daily). Neither patients nor investigators were masked to treatment allocation. The primary end point was ipsilateral breast tumor recurrence (IBTR), analyzed according to the modified intention-to-treat analysis. We assumed a 5-year IBTR rate of 4% in the WBI group to exclude a 2% increase in the APBI group (90% power; noninferiority margin hazard ratio [HR], 1.5).
Between 2007 and 2019, 3,309 patients were randomly assigned (1,652 to APBI, 1,657 to WBI); 84 were excluded from the analysis. The median follow-up was 97.5 months. The 5-year cumulative IBTR incidence was 1.0% (95% CI, 0.6 to 1.6) for APBI and 0.8% (95% CI, 0.5 to 1.4) for WBI. The HR for APBI versus WBI was 1.18 (90% CI, 0.63 to 2.20) with the upper confidence limit crossing the prespecified noninferiority margin.
At 5 years, the cumulative incidence of IBTR is exceptionally low (≤1%) in both arms. Although formal statistical noninferiority was not demonstrated because the upper confidence limit crossed the margin, the absolute difference was <0.2%. External-beam APBI therefore is a reasonable clinical alternative to WBI for low-risk patients.
PMID:
43044095
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 21
- Comments 0